NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins

(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news